SPC245
tildrakizumab
Status:
VeittApplication date:
19.12.2018Application published:
15.1.2019Grant published:
15.8.2020
Max expiry date:
20.2.2033Medicine name:
IlumetriMedicine for children:
No
Timeline
Today
19.12.2018Application
15.1.2019Publication
15.8.2020Registration
20.2.2033Expires
Marketing license
IS authorization number:
EU/1/18/1323/001-002Date:
12.10.2018
Foreign authorization number:
EU/1/18/1323Date:
17.9.2018
Owner
Name:
Merck Sharp & Dohme LLCAddress:
126 East Lincoln Ave., P.O. Box 2000, Rahway, NJ 07065 US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113 Reykjavík
Patent
Number:
EP2059534